Why Cepheid Is Skyrocketing Today
Shares jump on the news that the company is being bought out by Danaher.
A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.
Shares jump on the news that the company is being bought out by Danaher.
Cepheid's shares erase more than two years of gains after the company released its preliminary third quarter earnings report. Here's why.
There's super-cool science at work here, as well as multiple opportunities for investors.
Molecular diagnostic test company Cepheid stock dropped 12% today after reporting earnings last night. Is the move justified, or just market noise?
Molecular diagnostic company Cepheid may need to do some internal analyzing after its full-year outlook failed to excite investors.
Is this meaningful or just another movement?
It's win-win when these companies treat diseases and make a lot of money.
Is this meaningful or just another movement?
Is this meaningful or just another movement?
Sooner or later, operating cash flow that's all from adding back stock-based comp is unsustainable. Right now, there are 10 really bad offenders -- don't go near them.